Please try another search
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Anthony S. Marucci | 59 | 2003 | Founder, President, CEO & Director |
Marc E. Rothenberg | - | - | Member of Scientific Advisory Board |
Karen Lipton Shoos | 68 | 2001 | Independent Chair of the Board of Directors |
Carl H. June | 68 | - | Member of Scientific Advisory Board |
James J. Marino | 72 | 2017 | Independent Director |
Harry H. Penner | 77 | 1997 | Independent Director |
Keith L. Brownlie | 70 | 2017 | Independent Director |
Michel Nussenzweig | - | - | Member of Scientific Advisory Board |
Herbert J. Conrad | 89 | 2008 | Independent Director |
Louis M. Weiner | 70 | - | Member of Scientific Advisory Board |
Joseph P. Schlessinger | 77 | 2021 | Co-Founder & Member of Scientific Advisory Board |
Garry A. Neil | 69 | 2022 | Independent Director |
Rita I. Jain | 60 | 2023 | Independent Director |
Cheryl L. Cohen | 57 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review